市場調査レポート
商品コード
1402027
肺炎検査市場の2030年までの予測:製品タイプ、検査タイプ、検査方法、技術、エンドユーザー別、地域別の世界分析Pneumonia Testing Market Forecasts to 2030 - Global Analysis By Product Type, Type, Test Type, Method, Technology, End User and by Geography |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
肺炎検査市場の2030年までの予測:製品タイプ、検査タイプ、検査方法、技術、エンドユーザー別、地域別の世界分析 |
出版日: 2023年12月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
|
Stratistics MRCによると、世界の肺炎検査市場は2023年に6億5,513万米ドルを占め、2030年には11億2,277万米ドルに達すると予測され、予測期間中のCAGRは8.0%です。
肺炎検査と呼ばれる重要な診断手順は、肺炎(肺の気嚢に炎症を起こす呼吸器感染症)が存在するかどうかを判断するために使用されます。肺炎は細菌、ウイルス、真菌によって引き起こされることが多いです。治療を受けなければ、重篤な呼吸困難に陥る可能性があります。胸部X線検査で肺の異常を確認し、血液検査で感染の有無を判断し、呼吸器分泌物分析で原因を特定することができます。
米国国立衛生研究所(NIH)が2022年に発表した論文によると、肺炎球菌は米国における肺炎患者の最大15.0%、世界全体では27.0%を占めています。
人口の高齢化と伝染病リスク
肺炎検査市場を牽引する主要要因の1つは、高齢化社会への人口動態の変化です。高齢者は肺炎を含む呼吸器感染症にかかりやすいため、正確な検査方法の必要性が高まっています。さらに、この人口統計学的要因は、早期発見と、高齢化人口特有の医療ニーズに対応する市場の責任を浮き彫りにしています。
最先端診断システムの初期費用の高さ
肺炎検査市場にとっての障壁は、高度な診断技術に関連する初期費用です。高度な画像技術や分子診断のような最新機器は、初期費用が高額になる可能性があります。加えて、このような最新鋭の検査技術の市場浸透を遅らせ、特にリソースの限られた医療環境での採用を制限する可能性があります。
マルチプレックス検査用プラットフォームの開発
肺炎検査の市場開拓は、複数の病原体を同時に検出できるマルチプレックス検査プラットフォームの開発によってもたらされます。1回の検査で完全な診断データを提供し、診断手順を迅速化することで、これらのプラットフォームは生産性を向上させる。さらに、重複感染の発見と全体的な診断精度の向上は、マルチプレックス検査が特に役立つ2つの分野です。
医療システムにおける財政的制約
先進的な肺炎検査技術の普及は、医療システムにおける予算の制約によって脅かされています。限られた資金では、医療従事者のトレーニングへの投資や最先端の診断ツールの購入が難しくなる可能性があります。さらに、その結果、最先端の検査技術へのアクセスが不平等になり、肺炎診断の全体的な有効性が損なわれる可能性があります。
COVID-19パンデミックは医療セクターの力学と優先順位を変え、肺炎検査市場に大きな影響を与えました。パンデミックによって呼吸器系の健康への関心が高まり、診断ソリューションへのニーズが急増しているため、肺炎検査の技術革新は加速しています。その一方で、サプライチェーンの混乱、変動する医療支出、ピーク時の検査リソースに対する莫大な需要のような困難も、手ごわい障害となっています。さらに、パンデミックは、国際保健緊急事態において、スケーラブルで効果的な肺炎検査が果たす重要な役割を浮き彫りにし、感染症の性質の変化への革新と適応を業界に迫った。
予測期間中、ウイルス性肺炎分野が最大となる見込み
肺炎検査の市場シェアでは、ウイルス性肺炎分野が最大のシェアを占めると予測されます。ウイルス性肺炎は、インフルエンザや呼吸器合胞体ウイルス(RSV)のような呼吸器系ウイルスの流行や、新型コロナウイルスSARS-CoV-2が主要原因であったCOVID-19パンデミックのため、注目を集めています。ウイルス性肺炎に特化した診断ソリューションの需要が増加した結果、分子アッセイ、抗原検査、その他の診断技術が進歩しました。さらに、呼吸器系ウイルスの伝染性と正確かつ迅速な検査の必要性から、この分野は肺炎検査市場において重要な焦点となっています。
診断ラボ部門は予測期間中に最も高いCAGRが見込まれる
肺炎検査市場では、診断ラボ部門が最も高いCAGRで成長すると予測されます。画像検査、血液検査、分子診断など様々な診断手段を提供する診断検査室は、肺炎の徹底的かつ専門的な検査サービスの提供に不可欠です。診断検査施設は、診断技術の向上と、肺炎に対する迅速かつ正確な検査の必要性の高まりの結果として成長してきました。さらに、これらの施設は最先端の診断技術を採用し、大量の検査を効率的に処理するための設備が整っていることが多いです。
北米地域が肺炎検査の最大市場シェアを占めると予測されます。同地域の優位性は、強固な医療インフラ、最先端の診断技術、感染症の積極的な管理などに起因しています。さらに、肺炎検査の需要は、有利な償還政策、意識の高まり、北米における呼吸器感染症の有病率の高さによって牽引されています。
肺炎検査市場では、アジア太平洋のCAGRが最も高いと予測されます。呼吸器感染症の罹患率の上昇、人口の高齢化、医療インフラへの支出の増加、アジア太平洋諸国における医療へのアクセス強化の重視の高まりなどがその原因です。さらに、この地域の経済成長、医療技術の向上、早期診断の価値に対する一般市民の意識の高まりが、高い成長をもたらしています。
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
According to Stratistics MRC, the Global Pneumonia Testing Market is accounted for $655.13 million in 2023 and is expected to reach $1122.77 million by 2030 growing at a CAGR of 8.0% during the forecast period. A vital diagnostic procedure called pneumonia testing is used to determine whether pneumonia-a respiratory infection that inflames the lungs' air sacs-is present. Pneumonia is frequently caused by bacteria, viruses, or fungi. If treatment is not received, it can result in severe respiratory distress. Chest X-rays can be used to see abnormalities in the lungs; blood tests can determine whether an infection is present; and respiratory secretion analysis can pinpoint the cause.
According to a published article by the National Institutes of Health (NIH) in 2022, streptococcus pneumoniae accounts for up to 15.0% of pneumonia cases in the U.S. and 27.0% globally.
Population aging and contagious disease risk
One major factor driving the market for pneumonia testing is the demographic shift towards an aging population. There is an increased need for accurate testing procedures because elderly people are more vulnerable to respiratory infections, including pneumonia. Moreover, this demographic factor highlights early detection and the market's responsibility to meet the unique healthcare needs of the aging population.
High initial expenses for cutting-edge diagnostic systems
A barrier to the market for pneumonia testing is the upfront expenses linked to sophisticated diagnostic technologies. Modern instruments like sophisticated imaging technology and molecular diagnostics can be highly expensive up front. Additionally, this could slow down the market penetration of these cutting-edge testing techniques and restrict their adoption, especially in healthcare settings with limited resources.
Development of platforms for multiplex testing
Pneumonia testing market opportunities are presented by the development of multiplex testing platforms, which can detect multiple pathogens simultaneously. By delivering thorough diagnostic data in a single test and expediting the diagnostic procedure, these platforms increase productivity. Furthermore, discovering co-infections and enhancing overall diagnostic accuracy are two areas in which multiplex testing is especially helpful.
Financial limitations in healthcare systems
The widespread adoption of advanced pneumonia testing technologies is threatened by budgetary constraints in healthcare systems. Limited funds may make it more difficult to invest in healthcare personnel's training and to purchase cutting-edge diagnostic tools. Moreover, this may result in unequal access to cutting-edge testing techniques, which could compromise the overall efficacy of pneumonia diagnosis.
The COVID-19 pandemic has changed dynamics and priorities in the healthcare sector, which has had a significant effect on the market for pneumonia tests. Pneumonia testing innovation has accelerated due to the pandemic's increased focus on respiratory health and the pressing need for diagnostic solutions. On the other hand, difficulties like supply chain disruptions, fluctuating healthcare spending, and the tremendous demand for testing resources at peak times have also presented formidable obstacles. Additionally, the pandemic has brought to light the critical role that scalable and effective pneumonia testing plays in international health emergencies, and this has forced the industry to innovate and adapt to the changing nature of infectious diseases.
The Viral Pneumonia segment is expected to be the largest during the forecast period
In terms of market share for pneumonia tests, the viral pneumonia segment is projected to hold the largest share. Viral pneumonia has received a lot of attention because of the prevalence of respiratory viruses like influenza and respiratory syncytial virus (RSV) as well as the COVID-19 pandemic, which was primarily caused by the novel coronavirus SARS-CoV-2. Molecular assays, antigen tests, and other diagnostic techniques have advanced as a result of the growth in demand for viral pneumonia-specific diagnostic solutions. Moreover, this segment has become a crucial focal point in the pneumonia testing market due to the contagious nature of respiratory viruses and the need for accurate and quick testing.
The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period
In the market for pneumonia testing, the diagnostic laboratory segment is anticipated to grow at the highest CAGR. Diagnostic laboratories, which provide a variety of diagnostic modalities like imaging studies, blood tests, and molecular diagnostics, are essential to the provision of thorough and specialized testing services for pneumonia. Diagnostic laboratories have grown as a result of improvements in diagnostic technologies and the growing need for quick and accurate testing for pneumonia. Additionally, these facilities are frequently at the forefront of adopting cutting-edge diagnostic techniques and are outfitted to efficiently handle a high volume of tests.
The region of North America is projected to have the largest market share for pneumonia testing. The region's prominence is attributed to its strong healthcare infrastructure, cutting-edge diagnostic technologies, and proactive management of infectious diseases. Furthermore, the demand for pneumonia testing is driven by favorable reimbursement policies, heightened awareness, and a higher prevalence of respiratory infections in North America.
In the market for pneumonia testing, the Asia-Pacific region is projected to have the highest CAGR. The rising incidence of respiratory infections, the aging population, the increased spending on healthcare infrastructure, and the increased emphasis on enhancing healthcare accessibility in Asia-Pacific nations are some of the causes of this. Moreover, the high growth is a result of the region's growing economies, improvements in healthcare technologies, and increased public awareness of the value of early diagnosis.
Some of the key players in Pneumonia Testing market include Danaher , Abbott, F. Hoffmann-La Roche Ltd., Beckton and Dickinson Company, Cepheid, Biomerieux SA, Hologic Inc, Luminex Corporation, Meridian Bioscience, Inc., Bio Rad laboratories, OpGen, Quidel Corporation, AdvanDx, Thermo Fisher Scientific Inc., Beckman Coulter , Siemens Healthcare GmbH and Quest Diagnostics Incorporated .
In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.
In September 2023, Hologic and Bayer today announced an international partnership focused on improving breast cancer detection. The companies teamed up to deliver contrast-enhanced mammography (CEM) solutions across Europe, Canada and Asia Pacific. CEM, a highly sensitive, relatively low-cost breast imaging modality, combines digital mammography with contrast agent administration. It supports breast cancer diagnosis and guides treatment decisions.
In August 2023, Science and medical technology firm Danaher announced Monday that it has entered into an agreement to acquire Abcam, a Cambridge, U.K.-based supplier of antibodies, reagents, biomarkers, and assays. Under the agreement, Danaher will acquire all outstanding Abcam shares for $24 per share in cash, with a total enterprise value of approximately $5.7 billion, including Abcam's assumed debts and net of acquired cash.